mhurhangee/patent-ind-claim-en huggingface dataset:
A method for fabricating a part of polymeric material having fire-proof properties, comprising at least the following steps of: a) providing a part of polymeric material, and introducing said part into a reaction chamber, and then b) contacting the part with organometallic complexes of the formula M m R n , with: - M is a metal selected from aluminum, magnesium, zinc, manganese, cesium, and strontium; - m is an integer greater than 0; - n is an integer greater than 0; - R is selected from linear or branched C1-C4 alkyls, and SiR' groups where R' is a linear or branched C1-C4 alkyl, and with a first fluid under a pressure and temperature such that the first fluid is in supercritical state, so as to incorporate the organometallic complexes into the part, and then c) contacting the part with a second fluid, the second fluid being carbon dioxide, under a pressure and temperature such that the second fluid is in supercritical state, so as to transform the organometallic complexes into metal carbonates of the formula M m (CO 3 ) n . a) providing a part of polymeric material, and introducing said part into a reaction chamber, and then b) contacting the part with organometallic complexes of the formula M m R n , with: - M is a metal selected from aluminum, magnesium, zinc, manganese, cesium, and strontium; - m is an integer greater than 0; - n is an integer greater than 0; - R is selected from linear or branched C1-C4 alkyls, and SiR' groups where R' is a linear or branched C1-C4 alkyl, and with a first fluid under a pressure and temperature such that the first fluid is in supercritical state, so as to incorporate the organometallic complexes into the part, and then - M is a metal selected from aluminum, magnesium, zinc, manganese, cesium, and strontium; - m is an integer greater than 0; - n is an integer greater than 0; - R is selected from linear or branched C1-C4 alkyls, and SiR' groups where R' is a linear or branched C1-C4 alkyl, c) contacting the part with a second fluid, the second fluid being carbon dioxide, under a pressure and temperature such that the second fluid is in supercritical state, so as to transform the organometallic complexes into metal carbonates of the formula M m (CO 3 ) n .
A compound selected from the compounds having the following structure or a salt thereof: wherein R is -(CH 2 ) n -R X1 ; R X1 is : ∗ Denotes point of attachment of the R X1 group to (CH 2 ) n connecting group R X4 is a halogen selected from F, Cl, Br, I; n = 0-10; X is selected from the group consisting of -H, -OH, -OMe, -O-allyl, -F, -OEt, -OPr, - OCH 2 CH 2 OCH 3 and -azido; R' is selected from the group consisting of -Ac; -P(N(iPr) 2 (O(CH 2 ) 2 )CN; -Bz and -SiMe 2 tBu; R" is selected from the group consisting of H, DMT and triphosphate (-P(O)(OH)-OP(O)(OH)-O-P(O)(OH) 2 ) or a salt thereof. R is -(CH 2 ) n -R X1 ; R X1 is : ∗ Denotes point of attachment of the R X1 group to (CH 2 ) n connecting group R X4 is a halogen selected from F, Cl, Br, I; n = 0-10; X is selected from the group consisting of -H, -OH, -OMe, -O-allyl, -F, -OEt, -OPr, - OCH 2 CH 2 OCH 3 and -azido; R' is selected from the group consisting of -Ac; -P(N(iPr) 2 (O(CH 2 ) 2 )CN; -Bz and -SiMe 2 tBu; R" is selected from the group consisting of H, DMT and triphosphate (-P(O)(OH)-OP(O)(OH)-O-P(O)(OH) 2 ) or a salt thereof.
A device for auricular punctual stimulation of a patient, comprising an electrical current generator for generating electrical stimulation pulses and electrical lines for connecting to one electrode each to be positioned on the ear , at least two of which electrodes can be acted on by the electrical stimulation pulses, and further comprising measurement means for determining at least one physiological measured value of the patient, wherein the measurement means are configured to determine the at least one physiological measured value by means of impedance plethysmography via the electrodes , wherein the electrical current generator is configured to generate an alternating current, which can be introduced into the ear via two of the electrical lines and the associated electrodes , and wherein the measurement means have a measuring circuit for measuring a tissue impedance tapped between two electrodes , characterised in that the current generator is configured to generate a plurality of sequences of electrical stimulation pulses with pauses between the sequences and to generate the alternating current in at least one of the pauses.
Closing assembly for an in the ear part of a hearing device, the in the ear part having a cavity for holding an output transducer, the in the ear part having an opening and the closing assembly being configured to fit into the opening, the closing assembly comprising: an insert part having an insert part opening for receiving and mounting a connecting member , the connecting member configured for mechanically coupling the in the ear part to a behind the ear part of the hearing device, and a cover part comprising a recess ; characterized in that the recess is configured for receiving and mounting the insert part, and in that the recess locks the insert part with respect to the cover part . an insert part having an insert part opening for receiving and mounting a connecting member , the connecting member configured for mechanically coupling the in the ear part to a behind the ear part of the hearing device, and a cover part comprising a recess ; characterized in that the recess is configured for receiving and mounting the insert part, and in that the recess locks the insert part with respect to the cover part .
A method of producing one or more moulded bodies, the method comprising the steps of: a. layer-wise construction of one or more moulded bodies by means of repeated application of particulate material in a 3D printing process, the particulate material being characterized by a single-phase coating or covering with one or more materials, the coating or covering being a binder, b. a pre-solidification step for achieving pre-solidification of the moulded body, wherein the pre-solidification step is performed by using a solvent and a polymerization reaction by selectively printing a solvent on the binder-covered particulate material, c. an unpacking step in which the non-solidified particulate material is separated from the pre-solidified moulded body, d. a final solidification step, in which the moulded body obtains its final strength, by the action of thermal energy, wherein the binder contains polymerizable monomers and wherein the coating or coveringcontains substances for starting a polymerization with the binder. a. layer-wise construction of one or more moulded bodies by means of repeated application of particulate material in a 3D printing process, the particulate material being characterized by a single-phase coating or covering with one or more materials, the coating or covering being a binder, b. a pre-solidification step for achieving pre-solidification of the moulded body, wherein the pre-solidification step is performed by using a solvent and a polymerization reaction by selectively printing a solvent on the binder-covered particulate material, c. an unpacking step in which the non-solidified particulate material is separated from the pre-solidified moulded body, d. a final solidification step, in which the moulded body obtains its final strength, by the action of thermal energy, wherein the binder contains polymerizable monomers and wherein the coating or coveringcontains substances for starting a polymerization with the binder.
Acrylate-free cosmetic O/W emulsion comprising a) at least one substance selected from the group comprising alkali metal alkyl sulfates and alkali metal alkyl phosphates, wherein the alkyl group has in each case 16 to 18 carbon atoms, b) hydroxypropyl starch phosphate, and c) glycerol monostearate and/or sorbitan monostearate. a) at least one substance selected from the group comprising alkali metal alkyl sulfates and alkali metal alkyl phosphates, wherein the alkyl group has in each case 16 to 18 carbon atoms, b) hydroxypropyl starch phosphate, and c) glycerol monostearate and/or sorbitan monostearate.
Combustion system for a turbine, notably for a turbine having a thermodynamic cycle with a recuperator, for the production of energy, comprising a continuous-flow tubular combustion chamber and a heat exchanger for the exchange of heat between the intake gases for said combustion chamber and the burnt gases coming from said combustion chamber, characterized in that said heat exchanger is an annular counter-current heat exchanger arranged around said combustion chamber .
A process for producing an assembly of at least one micellar casein retentate and at least one pea protein, said process comprising the steps consisting in: - preparing an aqueous composition comprising at least one pea protein by incorporating said at least one pea protein into water; - reducing the pH of said aqueous composition to a value of less than or equal to 4.5, in order to obtain an acidified composition; - raising the pH of said acidified aqueous composition to a value of between 5 and 8, preferably between 5.5 and 7.5, even more preferentially to a value of between 6 and 7, and ideally to a value of 7; - introducing at least one micellar casein retentate into said aqueous composition obtained after the pH has been raised, in order to obtain a mixture; - homogenizing the mixture obtained. - preparing an aqueous composition comprising at least one pea protein by incorporating said at least one pea protein into water; - reducing the pH of said aqueous composition to a value of less than or equal to 4.5, in order to obtain an acidified composition; - raising the pH of said acidified aqueous composition to a value of between 5 and 8, preferably between 5.5 and 7.5, even more preferentially to a value of between 6 and 7, and ideally to a value of 7; - introducing at least one micellar casein retentate into said aqueous composition obtained after the pH has been raised, in order to obtain a mixture; - homogenizing the mixture obtained.
An apparatus , comprising: a set of first access lines (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) for a memory array (102, 200, 405, 405-a...405-d) that extend in a first direction; a set of second access lines (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) for the memory array (102, 200, 405, 405-a... 405-d) that extend in a second direction; a set of first sockets each coupled with an end of a respective first access line of the set (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) and with a respective first driver of a set of first drivers, the set of first sockets arranged in a first row (530, 530-a... 530-c) that extends in a third direction; and a set of second sockets each coupled with an end of a respective second access line of the set (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) and with a respective second driver of a set of second drivers, the set of second sockets arranged in a second row (530, 530-a... 530-c) that is parallel to the first row and extends in the third direction, the third direction non-parallel to both the first direction and the second direction. a set of first access lines (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) for a memory array (102, 200, 405, 405-a...405-d) that extend in a first direction; a set of second access lines (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) for the memory array (102, 200, 405, 405-a... 405-d) that extend in a second direction; a set of first sockets each coupled with an end of a respective first access line of the set (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) and with a respective first driver of a set of first drivers, the set of first sockets arranged in a first row (530, 530-a... 530-c) that extends in a third direction; and a set of second sockets each coupled with an end of a respective second access line of the set (110, 115, 210, 210-a, 210-b, 215, 215-a, 310, 310-a...310-f, 315, 315-a...315-f, 505, 515) and with a respective second driver of a set of second drivers, the set of second sockets arranged in a second row (530, 530-a... 530-c) that is parallel to the first row and extends in the third direction, the third direction non-parallel to both the first direction and the second direction.
A refrigeration apparatus comprising: a main body portion comprising a closable box which defines a refrigeration compartment ; a plurality of bimetallic strips arranged on each inner surface of the main body portion, the bimetallic strips connectable to a voltage supply such that, on application of a voltage to the bimetallic strips, the bimetallic strips deform causing a force to be exerted outwards from the inner surface. a main body portion comprising a closable box which defines a refrigeration compartment ; a plurality of bimetallic strips arranged on each inner surface of the main body portion, the bimetallic strips connectable to a voltage supply such that, on application of a voltage to the bimetallic strips, the bimetallic strips deform causing a force to be exerted outwards from the inner surface.
A pharmaceutical formulation comprising a buffer, a tonicity agent, and a chorionic gonadotropin carboxy terminal peptide (CTP)-modified polypeptide consisting of a Factor VII coagulation factor and three chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein said polypeptide does not include a signal peptide, and wherein said formulation is at a pH of 6.4 to 6.5, said buffer is 20 mM citrate and 13.3 mM glycine, and said tonicity agent is 150 mM sodium chloride.
Multi-part rail wheel having a wheel tyre , a wheel body , an elastic body arranged between the wheel tyre and the wheel body , via which the wheel tyre is supported on the wheel body , as well as having at least one tension element attached to the wheel body away from the one end side, via which tension element the elastic body is tensioned against the wheel body and the wheel tyre by means of tension means acting on the wheel body , wherein the wheel body consists of a light metal material at least in the region, against which the tension means acts, characterised in that on the end side of the wheel body axially opposite the tension element is provided at least one annular counter bearing element as the counter bearing on which the tension means act, said counter bearing element consisting of a material which has a higher strength than the light metal material of the wheel body , wherein the counter bearing element sits in a receiving portion aligned coaxially in relation to the rotational axis (D) of the rail wheel and formed into the wheel body as a depression.
A method of making a highly fluorinated polymer comprising: (i) polymerizing one or more perfluorinated monomers in an aqueous emulsion polymerization in the presence of a polymerizable fluorinated emulsifier to form the highly fluorinated polymer, wherein the polymerizable fluorinated emulsifier is selected from the group consisting of: CF 2 =CF-(CF 2 ) m -O-(CF 2 ) p -[O-(CF 2 ) r ] s -Y (I) CF 2 =CF-(CF 2 ) m -O-(CF 2 ) p -[O-(CF(CF 3 )-CF 2 )] t -[O-CF(CF 3 )] v -Y (II); where Y is COOM or SO 3 M, m is an integer selected from 0 to 5, p is at least 1, r is an integer selected from 0 to 5, s is an integer selected from 1 to 5, t is an integer selected from 1 to 5, v is an integer selected from 1to 5, and M is H, an alkali metal, or NH 4 and wherein the amount of polymerizable fluorinated emulsifier is less than 1 wt % based on the total weight of monomers used; (ii) isolating the highly fluorinated polymer. (i) polymerizing one or more perfluorinated monomers in an aqueous emulsion polymerization in the presence of a polymerizable fluorinated emulsifier to form the highly fluorinated polymer, wherein the polymerizable fluorinated emulsifier is selected from the group consisting of: CF 2 =CF-(CF 2 ) m -O-(CF 2 ) p -[O-(CF 2 ) r ] s -Y (I) CF 2 =CF-(CF 2 ) m -O-(CF 2 ) p -[O-(CF(CF 3 )-CF 2 )] t -[O-CF(CF 3 )] v -Y (II); where Y is COOM or SO 3 M, m is an integer selected from 0 to 5, p is at least 1, r is an integer selected from 0 to 5, s is an integer selected from 1 to 5, t is an integer selected from 1 to 5, v is an integer selected from 1to 5, and M is H, an alkali metal, or NH 4 and wherein the amount of polymerizable fluorinated emulsifier is less than 1 wt % based on the total weight of monomers used; (ii) isolating the highly fluorinated polymer.
A method of enhancing a nucleic acid polymerase reaction, the method comprising: a. forming a nucleic acid polymerase reaction composition comprising: i. a template nucleic acid, ii. a nucleic acid polymerase, iii. a mixture of nucleotides or nucleotide analogs, and iv. at least one compound of formula (I); and b. incubating the nucleic acid polymerase reaction composition under conditions allowing a nucleic acid polymerization reaction, wherein the at least one compound of formula (I) increases the processivity, rate, or fidelity of the nucleic acid polymerase reaction; wherein the compound of formula (I) is represented by: wherein, independently at each occurrence: m is 1,2 or 3; n is 0, 1 or 2; p is 0, 1 or 2; Ar1 is optionally substituted aryl; Ar2 is selected from 5- and 6-membered monocyclic aromatic rings and 9- and 10-membered fused bicyclic rings comprising two 5- and/or 6-membered monocyclic rings fused together, where at least one of the two monocyclic rings is an aromatic ring, where Ar2 is optionally substituted with one or more substituents selected from halide, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, E-CO 2 R 0 , E-CONH 2 , E-CHO, E-C(O)NH(OH), E-N(R 0 ) 2 , and E-OR 0 , where E is selected from a direct bond and C 1 -C 6 alkylene; and R° is selected from H, C 1 -C 6 alkyl and C 1 -C 6 haloalkyl, M is selected from hydrogen, halogen and C 1 -C 4 alkyl; and L is a linking group; or a solvate, hydrate, tautomer, chelate or salt thereof. a. forming a nucleic acid polymerase reaction composition comprising: i. a template nucleic acid, ii. a nucleic acid polymerase, iii. a mixture of nucleotides or nucleotide analogs, and iv. at least one compound of formula (I); and i. a template nucleic acid, ii. a nucleic acid polymerase, iii. a mixture of nucleotides or nucleotide analogs, and iv. at least one compound of formula (I); and b. incubating the nucleic acid polymerase reaction composition under conditions allowing a nucleic acid polymerization reaction, wherein the at least one compound of formula (I) increases the processivity, rate, or fidelity of the nucleic acid polymerase reaction; m is 1,2 or 3; n is 0, 1 or 2; p is 0, 1 or 2; Ar1 is optionally substituted aryl; Ar2 is selected from 5- and 6-membered monocyclic aromatic rings and 9- and 10-membered fused bicyclic rings comprising two 5- and/or 6-membered monocyclic rings fused together, where at least one of the two monocyclic rings is an aromatic ring, where Ar2 is optionally substituted with one or more substituents selected from halide, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, E-CO 2 R 0 , E-CONH 2 , E-CHO, E-C(O)NH(OH), E-N(R 0 ) 2 , and E-OR 0 , where E is selected from a direct bond and C 1 -C 6 alkylene; and R° is selected from H, C 1 -C 6 alkyl and C 1 -C 6 haloalkyl, M is selected from hydrogen, halogen and C 1 -C 4 alkyl; and L is a linking group;
An endovascular drug delivery device configured for being deployed in a dural venous sinus (DVS) of a patient, the drug delivery device comprising: a self-expanding distal anchor configured for being introduced into, and disposed within, an intracranial subarachnoid space (ISAS) of the patient via the DVS; an elongate tubular body coupled to the distal anchor and configured for being at least partially disposed within the DVS when the anchor is disposed within the ISAS, the elongate tubular body comprising a lumen that is in fluid communication with a therapeutic agent outflow opening in the distal anchor for allowing a therapeutic agent to flow from the lumen of the elongate tubular body out the therapeutic agent outflow opening and into the ISAS when the distal anchor is secured therein, characterized in that the endovascular drug delivery device further comprises a valve (209, 2209, 2209") disposed in or over the therapeutic agent outflow opening and configured to allow the therapeutic agent to flow out of the therapeutic agent outflow opening while preventing cerebrospinal fluid (CSF) in the ISAS from entering into the lumen of the elongate tubular body . a self-expanding distal anchor configured for being introduced into, and disposed within, an intracranial subarachnoid space (ISAS) of the patient via the DVS; an elongate tubular body coupled to the distal anchor and configured for being at least partially disposed within the DVS when the anchor is disposed within the ISAS, the elongate tubular body comprising a lumen that is in fluid communication with a therapeutic agent outflow opening in the distal anchor for allowing a therapeutic agent to flow from the lumen of the elongate tubular body out the therapeutic agent outflow opening and into the ISAS when the distal anchor is secured therein, characterized in that the endovascular drug delivery device further comprises a valve (209, 2209, 2209") disposed in or over the therapeutic agent outflow opening and configured to allow the therapeutic agent to flow out of the therapeutic agent outflow opening while preventing cerebrospinal fluid (CSF) in the ISAS from entering into the lumen of the elongate tubular body .
Mounting assembly of a component for a vehicle, comprising the component , a load-bearing structural element of the vehicle and at least one mounting means , wherein the component is mounted on the load-bearing structural element of the vehicle by means of the at least one mounting means , wherein the mounting means has a clamping element (4.1, 4.2), wherein, in a normal state, the clamping element (4.1, 4.2) reinforces the mounting of the component via the mounting means , wherein, in the case of the action of an external force (F), the clamping element (4.1, 4.2) automatically transfers into an accident state in which the clamping element (4.1, 4.2) loosens the mounting of the component via the mounting means , characterized in that the clamping element (4.1, 4.2) comprises at least two wedges (4.1, 4.2), the side surfaces thereof being superimposed at least in the normal state and being displaced relative to one another in the case of the action of the external force (F), wherein a projecting element is provided, wherein the projecting element has a projection relative to the load-bearing structural element and is connected to a wedge (4.1, 4.2) or is integral therewith, such that in the case of the action of the external force (F) from the direction of the projection, the projecting element is affected by the action of force before the load-bearing structural element and acts on the wedge (4.1, 4.2).